FDA Advisory Committee Meetings: What They Are, Why They Happen, and What They Mean for Regulatory Professionals
The November, 2014 issue of the TOPRA Regulatory Rapporteur features an article entitled “FDA Advisory Committee Meetings: What they are, why they happen, and what they mean for regulatory professionals.”
FDA Advisory Committee meetings have a tremendous impact on whether a medical product ever makes it to market. In this article, learn:
- Why an Advisory Committee meeting is critical to a product’s success
- What influence these meetings have on companies’ development plans
- How to prepare for an Advisory Committee meeting
For the full article, please complete the form.
ABOUT THE AUTHOR
Virginia Cox, JD, is a Senior Consultant and 3D Communications lead. Before joining 3D, Virginia was the Associate Commissioner for the Office of External Affairs at the U.S. Food and Drug Administration (FDA). Her FDA experience, along with her role as a Communications Lead on numerous 3D FDA Advisory Committee projects, uniquely qualifies her to provide important perspectives on this topic. Connect with Virginia on LinkedIn.